TY - JOUR
T1 - A human STAT3 gain-of-function variant drives local Th17 dysregulation and skin inflammation in mice
AU - Toth, Kelsey A.
AU - Schmitt, Erica G.
AU - Kolicheski, Ana
AU - Greenberg, Zev J.
AU - Levendosky, Elizabeth
AU - Saucier, Nermina
AU - Trammel, Kelsey
AU - Oikonomou, Vasileios
AU - Lionakis, Michail S.
AU - Klechevsky, Eynav
AU - Kim, Brian S.
AU - Schuettpelz, Laura G.
AU - Saligrama, Naresha
AU - Cooper, Megan A.
N1 - Publisher Copyright:
© 2024 Toth et al.
PY - 2024/8/5
Y1 - 2024/8/5
N2 - Germline gain-of-function (GOF) variants in STAT3 cause an inborn error of immunity associated with early-onset poly-autoimmunity and immune dysregulation. To study tissue-specific immune dysregulation, we used a mouse model carrying a missense variant (p.G421R) that causes human disease. We observed spontaneous and imiquimod (IMQ)-induced skin inflammation associated with cell-intrinsic local Th17 responses in STAT3 GOF mice. CD4+ T cells were sufficient to drive skin inflammation and showed increased Il22 expression in expanded clones. Certain aspects of disease, including increased epidermal thickness, also required the presence of STAT3 GOF in epithelial cells. Treatment with a JAK inhibitor improved skin disease without affecting local Th17 recruitment and cytokine production. These findings collectively support the involvement of Th17 responses in the development of organ-specific immune dysregulation in STAT3 GOF and suggest that the presence of STAT3 GOF in tissues is important for disease and can be targeted with JAK inhibition.
AB - Germline gain-of-function (GOF) variants in STAT3 cause an inborn error of immunity associated with early-onset poly-autoimmunity and immune dysregulation. To study tissue-specific immune dysregulation, we used a mouse model carrying a missense variant (p.G421R) that causes human disease. We observed spontaneous and imiquimod (IMQ)-induced skin inflammation associated with cell-intrinsic local Th17 responses in STAT3 GOF mice. CD4+ T cells were sufficient to drive skin inflammation and showed increased Il22 expression in expanded clones. Certain aspects of disease, including increased epidermal thickness, also required the presence of STAT3 GOF in epithelial cells. Treatment with a JAK inhibitor improved skin disease without affecting local Th17 recruitment and cytokine production. These findings collectively support the involvement of Th17 responses in the development of organ-specific immune dysregulation in STAT3 GOF and suggest that the presence of STAT3 GOF in tissues is important for disease and can be targeted with JAK inhibition.
UR - http://www.scopus.com/inward/record.url?scp=85195627462&partnerID=8YFLogxK
U2 - 10.1084/jem.20232091
DO - 10.1084/jem.20232091
M3 - Article
C2 - 38861030
AN - SCOPUS:85195627462
SN - 0022-1007
VL - 221
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 8
M1 - e20232091
ER -